Metronidazole Polpharma

Metronidazole, the active ingredient in Metronidazole Polpharma, is a nitroimidazole antibiotic presented as an intravenous solution for intravenous use. It is indicated for the treatment of anaerobic bacterial infections and selected protozoal diseases in both adult and pediatric patients, administered under the direction of a qualified healthcare professional.

GNH USA supplies Metronidazole Polpharma as a licensed, GDP‑compliant international pharmaceutical supplier, providing the product to hospitals, clinics and procurement teams worldwide under strict quality‑assured conditions. The company adheres to EU GMP standards and offers reliable logistics for timely delivery.

Metronidazole is a nitroimidazole antibiotic that targets anaerobic bacteria and certain protozoa.

- Anaerobic bacterial infections: eliminates infection by killing susceptible anaerobic organisms. - Trichomoniasis: eradicates Trichomonas vaginalis causing vaginal infection. - Amoebiasis: treats intestinal infection caused by Entamoeba histolytica. - Bacterial vaginosis: restores normal vaginal flora by reducing overgrowth of anaerobes. - Clostridioides difficile infection: reduces toxin‑producing C. difficile in the colon.

Metronidazole may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: mild to moderate stomach upset. - Metallic taste: transient metallic sensation in the mouth. - Headache: mild headache. - Diarrhea: loose stools.

Serious or Rare Side Effects: - Severe allergic reaction: rash, itching, swelling, or anaphylaxis. - Peripheral neuropathy: tingling or numbness in extremities. - Seizures: rare central nervous system events. - Hepatotoxicity: elevated liver enzymes or jaundice.

Before using Metronidazole Polpharma, consider the following precautions.

- Pregnancy: use only if clearly needed, as safety data are limited. - Breastfeeding: evaluate risk, drug may be excreted in milk. - Liver disease: dose adjustment may be required in hepatic impairment. - Alcohol consumption: avoid during treatment and for 48 hours after, to prevent disulfiram‑like reaction. - Drug‑induced neutropenia: monitor blood counts in prolonged therapy. - Store below 25°C: keep in original container, protect from light and moisture.

Metronidazole can interact with other medicines, affecting efficacy or safety.

Major Interactions (Avoid): - Disulfiram: concurrent use can cause severe flushing, tachycardia, and hypotension. - Warfarin: may increase anticoagulant effect, raising bleeding risk. - Lithium: can raise lithium levels, leading to toxicity.

Moderate Interactions (Monitor Closely): - Cimetidine: may increase metronidazole plasma concentrations. - Phenobarbital: may reduce metronidazole levels, decreasing effectiveness. - Alcohol: can cause a disulfiram‑like reaction; advise avoidance.